High-dose intravenous immunoglobulin therapy induces and maintains complete remission for polyarteritis nodosa

Kazu Ode¹, Yoshinori Taniguchi¹, Yoshitaka Kumon², Yoshio Terada¹

1. Department of Endocrinology, Metabolism and Nephrology, Kochi University School of Medicine, Nankoku, Japan.
2. Division of Rheumatology, Chikamori Hospital, Kochi, Japan

Abstract
We report a case of successful high-dose intravenous immunoglobulin (IVIG) use in a patient with refractory polyarteritis nodosa (PAN). Treatments with prednisolone (PSL) and various types of immunosuppressants including methotrexate (MTX) and intravenous cyclophosphamide (IVCY) were unsuccessful, and then, high-dose IVIg therapy was added. High-dose IVIG therapy improved all symptoms including high fever, arthralgia, mononeuritis multiplex and indurated erythema due to PAN. Moreover, serum inflammatory markers were also normalized. High-dose IVIG is maintaining complete remission for PAN without flare-up for additional 4 years. Therefore, high-dose IVIG therapy might be considered as a first-line therapy in patients with PAN or alternative therapy in refractory PAN.

Key words
Intravenous immunoglobulin, Polyarteritis nodosa, Refractory, Remission

1 Introduction
Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries, with occasional involvement of small muscular arteries. The disease can affect any organ of the body because systemic arteries are involved. Since the clinical course of PAN shows chronic pattern and life-threatening events are frequently revealed, the long-term administration of immunosuppressants is known as the standard of care [1]. Recently, the effects of high-dose intravenous immunoglobulin (IVIG) have been described for various rheumatic disorders, including PAN [2–5]. We herein report successful high-dose IVIG use in a patient with refractory PAN.

2 Case presentation
A 36-year-old Japanese woman was admitted to our hospital on September 2008 with high fever, general fatigue, arthralgia, numbness of the right upper and left lower extremities and indurated erythema. Livedo reticularis and indurated erythema (see Figure 1A) were revealed in the lower extremities. Regarding laboratory data, the white blood cell count was 9200/μl, hemoglobin level was 11.5 g/dl, and platelet count was 33.4×10⁴/μl. Erythrocyte sedimentation rate (ESR)
was 101 mm/hr, C-reactive protein (CRP) level was 5.4 mg/dl, and an elevated serum complement level (CH50, 59.4/ml) was shown. Anti-nuclear antibody was positive at 1:1280 with a centromere pattern. Serum hepatitis B surface antigen (HBsAg), anti-neutrophil cytoplasmic antibody (ANCA), anti-Parvovirus B19-IGM, Epstein-Barr virus (EBV) viral capsid antigens (VCA)-IGM, EBV early antigen-diffuse and restricted antibody (EA-DR)-IGG and EBV EA-DR-IgA were all negative. Urine analysis, renal and hepatic function tests were all within normal range. The nerve conduction study showed that the conduction velocity was lowered in the right ulnar, left tibial and sural nerves (both sensory and motor), indicating mononeuritis multiplex. An incisional skin biopsy specimen obtained from the indurated erythema of lower extremities (Figure 1A) demonstrated necrotizing arteritis with fibrinoid degeneration involving a medium-sized artery from the deep dermis to a fatty layer of the subcutaneous dermis (see Figure 1B). 3D-CT angiography showed an aneurysmal change in the celiac artery. She was diagnosed as systemic PAN based on these findings, and was initially treated with methotrexate (MTX), 8 mg weekly, and prednisolone (PSL), 40 mg daily, after intravenous steroid pulse therapy. Because of the poor response of erythema and mononeuritis multiplex to this treatment, six courses of intravenous cyclophosphamide (IVCY) pulse therapy, 600 mg/m² at an interval of every 4 weeks, was initiated. This treatment provided neurological relief from numbness and pain, however, PAN flared up with a high fever, erythema and exacerbation of neuritis in 2009. In addition to PSL, 15 mg daily, and MTX, 8 mg weekly, high-dose IVIG at a dose of 0.4 g/kg/day for five consecutive days was started. After the completion of the first course of high-dose IVIG, all symptoms of PAN including high fever, arthralgia, mononeuritis multiplex and erythema were dramatically improved. Moreover, inflammatory markers including CRP and ESR were also normalized. PSL was gradually tapered and MTX was changed to azathioprine (AZT) as a maintenance therapy after high-dose IVIG therapy. High-dose IVIG is currently maintaining a complete remission for PAN without flare-up for an additional 4 years (see Figure 2).

![Figure 1](A) Indurated erythema (arrow heads) and livedo reticularis were revealed at the lower extremities. (B) An incisional skin biopsy specimen obtained from indurated erythema demonstrated necrotizing arteritis with fibrinoid degeneration involving a medium-sized artery from the deep dermis to a fatty layer of subcutaneous dermis. Hematoxylin-eosin stain: original magnification: 100×.

![Figure 2](Clinical course.)
3 Discussion

PAN is a type of vasculitis affecting medium- to small-sized arteries. Recent studies estimated the prevalence as approximately 30 per one million adults in France and Sweden [6, 7].

In necrotizing systemic vasculitides associated with ANCA, IVIG therapy resulted in complete or partial responses in 45%-75% of patients [2]. To date, various mechanisms of action for IVIG in autoimmune disorders have been postulated, such as the blockade of Fcγ receptors on reticuloendothelial cells, alteration of T and/or B cell functions and the provision of anti-cytokine antibodies that alter immune responses and lead to the down-regulation of the immune response [3]. It was suggested that IVIG could prevent vasculitis by binding to the Fcγ receptor, thus preventing immune complex deposition in the vessels, or by neutralization of anti-endothelial antibodies that might cause inflamed vasculitis in PAN through anti-idiotypic antibodies. Thus, IVIG likely interacts with different components of the immune system, including cytokines, complement with Fc receptors and several cell surface molecules [2, 8].

It was previously reported that IVIG could be an important adjunct in selected patients with PAN, especially PAN associated with bacterial or viral infections. In such cases it led to a complete remission of the disease due to the neutralization of immune activation triggers, such as Parvovirus B19 and Streptococcus [9]. Thus, IVIG could be an excellent source of parvovirus B19-specific IGG and antibodies to streptococcal superantigens.

However, some reports have shown that the effect of IVIG therapy for PAN might be temporary [9, 10]. This might be explained by the lack of combined treatment with immunosuppressants, where IVIg is used as single agent, or by early tapering of immunosuppressants. Another cause might be the dose of IVIg required for successful treatment as demonstrated by the improvement of symptoms after the initial therapy with 0.5 g/kg/week and the recurrence of symptoms after the reduction to 0.25 g/kg/week. Therefore, they concluded that successful treatment might correlate with the dose of IVIG per body weight and week of treatment [10]. Therefore, in the present case, we guess that high-dose and multiple courses of IVIG therapy combined with immunosuppressants could be currently maintaining a complete remission for PAN without flare-up for an additional 4 years.

In summary, the present case suggests that high-dose IVIG therapy could induce and maintain complete remission for PAN over the long-term. Therefore, high-dose IVIG therapy might be considered as a first-line therapy in patients with PAN or alternative therapy in refractory PAN.

Disclosure statement

The authors have declared no conflicts of interest.

References


